{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:24:59Z","timestamp":1773426299830,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112947","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T20:53:10Z","timestamp":1687294390000},"page":"112947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population"],"prefix":"10.1016","volume":"190","author":[{"given":"M.","family":"Jongbloed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Steens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van de Lisdonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.K.M.","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2023.112947_bib1","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.112947_bib2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining synchronous oligometastatic non-small cell lung cancer: a systematic review","volume":"14","author":"Giaj-Levra","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.112947_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(\u2020)","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.112947_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.112947_bib5","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450)","volume":"13","author":"De Ruysscher","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.112947_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2023.112947_bib7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.112947_bib8","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2023.112947_bib9","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.112947_bib10","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.112947_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2021.11.009","article-title":"Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery","volume":"164","author":"Boch","year":"2022","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2023.112947_bib12","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.112947_bib13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.112947_bib14","unstructured":"Non-small Cell Lung Cancer. Version 3.2023: National comprehensive cancer network (NCCN); 2023 Available from: \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450\u3009."},{"issue":"12","key":"10.1016\/j.ejca.2023.112947_bib15","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer;a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.112947_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","article-title":"Strategies and technical challenges for imaging oligometastatic disease: recommendations from the european organisation for research and treatment of cancer imaging group","volume":"91","author":"deSouza","year":"2018","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ejca.2023.112947_bib17","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.112947_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2022.06.100","article-title":"Imaging-based prevalence of oligometastatic disease: a single-center cross-sectional study","volume":"114","author":"Christ","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ejca.2023.112947_bib19","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.21037\/tlcr-20-1065","article-title":"How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review","volume":"10","author":"Remon","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2023.112947_bib20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/JTO.0000000000000526","article-title":"Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?","volume":"10","author":"Kerr","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300299X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300299X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:14Z","timestamp":1760733734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300299X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":20,"alternative-id":["S095980492300299X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112947","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112947"}}